Tempest Therapeutics
TPST
53 hedge funds and large institutions have $244M invested in Tempest Therapeutics in 2014 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 2 closing their positions.
550% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 2
90% more capital invested
Capital invested by funds: $129M → $244M (+$115M)
71% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 7
26% more funds holding
Funds holding: 42 → 53 (+11)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$6.17M |
| 2 |
Asset Management One
Tokyo,
Japan
|
+$3.4M |
| 3 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$2.91M |
| 4 |
Jennison Associates
New York
|
+$2.8M |
| 5 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
+$1.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$6.17M |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$3.91M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.66M |
| 4 |
DVC
Deer VII & Co
Larchmont,
New York
|
-$876K |
| 5 |
KCM
Kingdon Capital Management
New York
|
-$421K |
TPST Hedge Fund Activity: Q3 2014 in Review
53 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q3 2014, worth a combined $244M — up 90% from $129M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new TPST positions and 2 closed out — a net gain of 11 holders — while 12 added to existing stakes and 7 trimmed.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $6.17M. The largest seller was Deerfield Management, cutting an estimated $6.17M.
- 53 institutional investors held Tempest Therapeutics (TPST) as of Q3 2014, up from 42 in Q2 2014.
- Funds reported $244M of Tempest Therapeutics stock for Q3 2014, up 90% quarter-over-quarter.
- 13 funds opened new Tempest Therapeutics positions in Q3 2014 and 2 closed out, a net change of +11 holders.
- The largest Tempest Therapeutics buyer in Q3 2014 was Cormorant Asset Management, an estimated $6.17M added.
- The largest Tempest Therapeutics seller in Q3 2014 was Deerfield Management, an estimated $6.17M sold.
Based on aggregated 13F filings for Q3 2014.